Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This product is a **combination vaccine** containing **Sabin-strain inactivated poliovirus vaccine (sIPV)** and **hepatitis A live attenuated vaccine**. - **Sabin-strain inactivated poliovirus vaccine (sIPV):** An inactivated (killed virus) vaccine derived from the attenuated Sabin strains of poliovirus, developed to provide immunity against poliomyelitis without the risk of vaccine-associated paralytic poliomyelitis. sIPV works by stimulating the immune system to produce neutralizing antibodies (IgG) against poliovirus types 1, 2, and 3[1][2][4][5]. The Sabin strains, originally developed for oral vaccines, are used inactivated in this formulation, reducing biosafety risks and avoiding transmission through fecal shedding[5]. - **Hepatitis A live attenuated vaccine:** A vaccine containing live, weakened hepatitis A virus that stimulates cellular and humoral immunity for long-term protection against hepatitis A infection. The vaccine is primarily indicated for **protection against both poliomyelitis and hepatitis A**. It is used in populations where combined prevention is needed, such as pediatric immunization programs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sabin-strain inactivated poliovirus vaccine + hepatitis A live attenuated vaccine.